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Abstract	
Cardiac	tissue	necrosis	secondary	to	coronary	artery	occlusion	is	one	of	the	most	common	
and	deadly	sterile	injuries	in	developed	countries.	In	this	issue	of	JCI,	Rieckmann	et	al.	
identified	and	characterized	antigen-specific	CD4+	T	helper	cells	that	developed	in	the	
context	of	myocardial	infarction	in	mice.	They	showed	that	myosin	heavy	chain	alpha	
(MYHCA)	is	a	dominant	cardiac	autoantigen	and	that	T	cells	with	T	cell	receptor	(TCR)	
specificity	to	MYHCA	acquired	a	regulatory	T	cell	(Treg)	phenotype	when	adoptively	
transferred	into	infarcted	mice,	which	mediated	a	cardioprotective	healing	response.	Thus,	
Rieckmann	et	al.	showed	that	an	acute	ischemic	insult	that	induces	sterile	inflammation	to	
the	heart,	promoted,	rather	than	limited,	protective	T	cell	autoimmunity.	Notably,	strategies	
that	support	antigen-specific	“Treg”	cell	response	may	limit	the	immune-inflammatory	
response	and	promote	cardiac	repair	after	acute	MI.	
	
Myocardial	infarction	and	the	inflammatory	response	
Cardiovascular	diseases	(CVD)	represent	a	major	cause	of	morbidity	and	mortality	
worldwide.	Despite	important	advances	in	the	treatment	of	acute	MI	(1),	the	occurrence	of	
MI	still	results	in	left	ventricular	dysfunction	in	up	to	50%	of	patients,	which	leads	to	the	
development	of	heart	failure.	Left	ventricular	dysfunction	is	the	strongest	predictor	of	
adverse	outcome	after	acute	MI,	and	is	associated	with	a	3	to	4-fold	increase	in	mortality	
risk.	In	developed	countries,	heart	failure	is	responsible	for	1-2%	of	all	health	expenditure,	
which	is	mostly	driven	by	repeated	hospital	admissions.	Thus,	there	is	a	considerable	need	
to	better	understand	the	remodelling	process	that	follows	an	ischemic	insult	to	the	heart	in	
order	to	limit	its	maladaptive	components	and	promote	a	beneficial	healing	process.	
	
Ischemic	injury	to	the	heart	releases	danger	signals	which	alert	and	activate	the	immune	
system	to	mount	a	sterile	inflammatory	response.	Both	innate	and	adaptive	immune	
mechanisms	become	involved	at	different	stages	after	MI;	and	current	knowledge	suggests	
that	suppressing	excessive	inflammation	may	limit	the	extension	of	infarct	size	and	promote	
a	better	reparative	(and	potentially	regenerative)	response	(2).	But,	what	do	we	know	about	
heart-specific	adaptive	T	cell	responses	and	how	do	the	new	results	compare	with	and	
extend	previous	knowledge?		
	
Adaptive	T	cell	responses	to	myocardial	injury		
Self-reactive	CD4+	T	cells	are	normally	deleted	in	the	thymus	by	a	process	called	negative	
selection.	Intriguingly,	CD4+	T	cells	with	TCRs	specific	for	some	tissue-restricted	self-antigens,	
including	cardiac	MYHCA,	escape	central	negative	selection,	(1,	3)	and	may,	therefore,	make	
the	respective	tissues	vulnerable	to	autoimmune	attack.	However,	non-deletional	tolerance	
mechanisms	maintain	immune	homeostasis.	For	example,	under	steady	state	conditions	in	
heart-draining	mediastinal	lymph	nodes	(medLN),	IRF8-dependent	conventional	dendritic	
cells	(DCs)	present	cardiac	MYHCA,	which	drive	the	expansion	and	the	differentiation	of	
MYHCA-specific	CD4+	T	cells	towards	a	protective	Treg	phenotype	(4).	Following	acute	MI,	
the	release	of	pro-inflammatory	cytokines	(e.g.,	HMGB1,	IL-1α,	IL-1β,	IL-6),	along	with	self-
antigens	promote	DC	maturation	and	activation,	and	license	MYHCA-specific	T	cells	to	adopt	
an	(IL-17/IFN-γ)	effector	phenotype	(4).	Although	this	sequence	may	set	the	background	for	
increased	susceptibility	to	autoimmune	attack	post	MI	(5),	in	the	absence	of	an	
autoimmune-prone	background,	tolerance	generally	remains	intact	and	pathologic	cardiac	
autoimmunity	fails	to	develop	(6).		
	
Rieckmann	and	colleagues	studied	the	post	MI	immune	response	in	more	detail.	They	
recovered	MYHCA-specific	CD4+	T	(TCR-M)	cells	from	MYHCA-TCR	transgenic	mice	and	
showed	that	after	MI,	the	transferred	cells	improved	heart	function	and	promoted	
myocardial	healing	(7).	The	authors	proposed	that	in	the	post	MI	setting	the	(preferential)	
differentiation	and	expansion	of	MYHCA-specific	CD4+	T	cells	towards	Tregs	was	responsible	
for	maintaining	immune	tolerance	and	providing	cardioprotective	effects.	This	conclusion	
was	based	on	an	experiment	in	which	the	adoptively	transferred	TCR-M	cells	that	
proliferated	and	accumulated	in	the	heart	(but	not	in	medLN)	displayed	a	higher	percentage	
of	Foxp3+	cells	in	mice	with	MI	compared	to	sham-operated	mice	(7).	In	another	mouse	
experiment,	adoptively	transferred	T	conventional	(Tconv)	cells	converted	to	Treg	in	situ	
within	the	heart	and	gave	rise	to	most	of	the	Foxp3+	TCR-M	cardiac	cells.	However,	the	
percentage	(50%)	of	TCR-M	Tconv	cells	that	acquired	Foxp3+	expression	in	the	ischemic	
heart	matched	sham-operated	mice	(7).	Thus,	the	cardiac	environment	per	se,	whether	
ischemic	or	not,	seems	to	favor	the	conversion	of	Tconv	cells	to	Tregs.	Given	cell	scarcity,	no	
further	characterization	of	these	heart-homing	TCR-M	cells	was	pursued.	Instead,	after	
transferring	cells	into	sham	or	MI	mice,	the	authors	performed	gene	expression	profiling	on	
medLN	TCR-M	cells.	When	cells	from	sham	mice	were	compared	with	those	from	MI	mice	
the	transcription	signature	revealed	enrichment	in	“pro-healing”	genes.	However,	no	
specific	enrichment	in	a	Treg	signature	was	detected;	and	genes	associated	with	T	helper	17	
and	T	follicular	helper	cell	responses	were	also	enriched	in	MI	medLN	TCR-M	cells	compared	
with	sham	mice	(7).	Further	characterization	of	TCR-M	cells	in	the	presence	or	absence	of	
MI	is	warranted	to	determine	the	mechanisms	responsible	for	their	cardioprotective	effects.	
	
Rieckmann	et	al.	also	analysed	the	endogenous	CD4+	T	cells	that	accumulate	in	the	hearts	
and	medLN	of	mice	after	MI.	The	results	revealed	a	unique	repertoire	signature	for	cardiac	T	
cells	with	preferential	expansion	of	clones	that	expressed	a	specific	TCR	beta	chain	variable	
region,	TCRBV-19	(7).	It	is	interesting	to	note	that	similarly	skewed	T	cell	responses	are	
induced	after	immunisation	of	mice	with	cardiac	myosin	or	heart	extract	(7),	and	have	also	
been	described	in	other	settings	associated	with	cardiovascular	injury,	including	dilated	
cardiomyopathy	in	humans	(8).	The	reasons	behind	this	preferential	usage	of	TCR	beta	chain	
variable	region	remain	unknown	and	merit	further	investigations.	It	will	be	interesting	to	
examine	whether	endogenous	T	cell	clones	play	beneficial	or	detrimental	roles	after	MI.	A	
recent	study	confirmed	the	occurrence	of	a	skewed	TCR	repertoire	in	cardiac	T	cells	of	
ischemic	failing	human	hearts,	indicative	of	tissue-specific	T	cell	expansion	(9).	Cardiac	T	
cells	of	ischemic	failing	hearts	displayed	memory	and	effector	phenotypes,	with	a	
predominance	of	T	helper	type	1	and	cytotoxic	CD8+	T	cells	(9),	suggesting	detrimental	
properties.		Thus,	while	the	immediate	post	MI	setting	may	still	be	conducive	to	the	
development	of	a	protective	Treg	response	(7),	a	failure	to	maintain	this	T	cell	homeostasis	
during	chronic	ischemia	may	contribute	to	the	progression	to	heart	failure.	Cells	equivalent	
to	IRF8-dependent	DCs	(CLEC9A+	DCs)	and	HLA-DR+	macrophages	showed	close	interactions	
with	cardiac	T	cells	in	the	failing	hearts,	suggesting	active	antigen	presentation.	The	use	of	
advanced	single	cell	TCR	sequencing	technologies	and	the	development	of	screening	
methods	with	peptide-major	histocompatibility	complex	may	help	identify	associated	
(auto)antigens.		
	
Cardioprotective	immunotherapies	
Can	we	harness	post	MI	CD4+	T	cell	responses	to	improve	patient	stratification	and	develop	
cardioprotective	immunotherapies?	Rieckmann	et	al.	combined	computed	tomography	with	
positron-emission	tomography	imaging	using	a	radiolabelled	C-X-C	motif	chemokine	receptor	
4	(CXCR4)	ligand	([68Ga]Pentixafor)	as	a	surrogate	of	T	cell	presence	in	the	heart	and	medLN.	
Interestingly,	medLN	were	significantly	enlarged	in	patients	with	MI	(n=22)	compared	to	
controls	(n=5).	Despite	the	small	size	of	the	latter	group,	and	that	the	“controls”	have	been	
included	in	the	study	as	part	of	an	endocrinological	investigation	for	suspected	benign	
Conn’s	adenoma,	the	results	are	consistent	with	a	local	expansion	of	the	T	cell	compartment	
in	patients	with	MI.	Additional	studies	are	necessary	to	better	characterize	this	response	
and	examine	whether	it	could	covey	any	prognostic	value	(e.g.,	better	healing	response	and	
improved	recovery	of	heart	function	at	follow-up).	A	recent	experimental	study	in	mice	and	
pigs	showed	that	controlled	CXCR4	blockade	through	bolus	injections	promoted	Treg	
mobilisation	(from	the	spleen)	and	Treg	homing	to	the	heart,	and	enhanced	their	immune-
regulatory	properties,	leading	to	reduced	infarct	size	and	improved	heart	function	(10).	If	
and	when	CXCR4	blockade	therapy	is	ready	for	use	in	patients	with	MI,	it	could	be	
interesting	to	evaluate	CXCR4	imaging	to	identify	the	most	suitable	candidates.	
	
Treg-targeted	therapies	have	the	potential	to	both	promote	cardiac	repair	after	MI	(11-13),	
and	limit	the	progression	of	atherosclerosis	(14).	An	interesting	Treg	promoting	therapy	
currently	trialled	in	patients	with	acute	coronary	syndromes	involves	administering	low-
dose	IL-2	(15,	16),	which	is	expected	to	selectively	expand	and	activate	Tregs	at	the	expense	
of	T	effector	cells	(17).	A	big	unknown,	however,	is	whether	Tregs	can	still	be	expanded	and	
maintained	locally	within	a	hostile	ischemic,	necrotic	and	inflammatory	microenvironment.	
The	study	by	Rieckmann	et	al.	reassuringly	suggests	that	such	Treg	promoting	therapies	may	
effectively	treat	acute	MI,	given	the	apparent	extraordinary	ability	of	the	cardiac	
environment	to	preserve,	maintain	or	even	promote	Treg	differentiation,	even	in	the	
presence	of	sterile	injury	and	danger	signals.	Nevertheless,	combination	with	therapies	that	
limit	effector	immune	mechanisms	(16,	18)	may	be	necessary	to	ensure	optimal	results.	
	
Finally,	future	studies	should	investigate	why	the	cardiac	environment	is	so	special	for	
promoting	Treg	differentiation.	In	this	regard,	it	is	interesting	to	note	that	fibro-adipogenic	
progenitors	in	skeletal	muscle	produce	IL-33	to	regulate	muscle	Treg	homeostasis	(19)	and	
promote	muscle	repair	(20).	Cardiac	fibroblasts	are	major	sources	of	IL-33,	whose	
production	and	release	are	further	promoted	by	biomechanical	stimuli	and	cell	death	(21).	
IL-33	could,	therefore,	at	least	in	part,	favor	local	differentiation,	activation	or	maintenance	
of	cardiac	Tregs,	which	is	a	hypothesis	that	merits	further	exploration.	
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